NewEdge Advisors’s Lucid Diagnostics LUCD Stock Holding History

NewEdge Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2	Closed	-$2	–	3887
2024 Q2	$2	Buy	+2	New	+$2	﹤0.01%	3774

Other funds holding LUCD

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NewEdge Advisors's LUCD Position: Q3 2024 in Review

NewEdge Advisors sold out of Lucid Diagnostics (LUCD) in Q3 2024, closing a stake of 2 shares — an estimated $2 sold.

NewEdge Advisors first reported a position in LUCD in Q2 2024 and held it in 1 quarter. The position peaked at $2 in Q2 2024. 29 funds tracked by Wall St. Rank hold LUCD as of Q3 2024.

NewEdge Advisors reported no remaining Lucid Diagnostics position as of Q3 2024 after selling out during the quarter.
NewEdge Advisors sold 2 Lucid Diagnostics shares in Q3 2024, an estimated $2.
NewEdge Advisors first reported a position in Lucid Diagnostics in Q2 2024 and held it in 1 quarter.
NewEdge Advisors's Lucid Diagnostics position peaked at $2 in Q2 2024.
29 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2024.

Based on NewEdge Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.